Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 4

1.

Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.

Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S, Payton JE, Ivanovich J, Goodfellow PJ, Le Beau M, Koboldt DC, Dooling DJ, Fulton RS, Bender RH, Fulton LL, Delehaunty KD, Fronick CC, Appelbaum EL, Schmidt H, Abbott R, O'Laughlin M, Chen K, McLellan MD, Varghese N, Nagarajan R, Heath S, Graubert TA, Ding L, Ley TJ, Zambetti GP, Wilson RK, Mardis ER.

JAMA. 2011 Apr 20;305(15):1568-76. doi: 10.1001/jama.2011.473.

2.

Secondary acute myeloid leukemia after successful treatment for osteosarcoma.

Mittal R, Ramaswamy NV, Pandita R, Al Bahar S, Khalifa N, Omar S.

Indian J Med Paediatr Oncol. 2010 Jan;31(1):33-5. doi: 10.4103/0971-5851.68852.

3.

Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.

Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ, Roddam PL, Roman E, Cartwright RA, Morgan GJ.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11592-7. Epub 2001 Sep 11. Erratum in: Proc Natl Acad Sci U S A 2001 Dec 18;98(26):15394.

4.

Association of CYP3A4 genotype with treatment-related leukemia.

Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR.

Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81.

Supplemental Content

Support Center